PER-029-19尚未招募未知
A PHASE 2 STUDY OF OLAPARIB IN COMBINATION WITH PEMBROLIZUMAB INPARTICIPANTS WITH PREVIOUSLY TREATED, HOMOLOGOUS RECOMBINATION REPAIR MUTATION (HRRM) AND/OR HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)-POSITIVE ADVANCED CANCER
Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,0 个研究点目标入组 7 人开始时间: 2019年12月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Has a histologically- or cytologically-confirmed advanced (metastatic and/or unresectable) solid tumor (except breast or ovarian cancers whose tumor has a germline or somatic BRCA mutation) that is not eligible for curative treatment and for which standard of care therapy has failed. Participants must have progressed on or be intolerant to standard of care therapies that are known to provide clinical benefit. There is no limit on the number of prior treatment regimens.
- •2.Has either centrally-confirmed known or suspected deleterious mutations in at least 1 of the specified 15 genes involved in HRR (ie, BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L) or centrally-confirmed HRD based on the Lynparza HRR-HRD assay.
- •3.Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology and confirmed in real time by BICR. BICR must confirm the presence of radiologically measurable disease per RECIST 1.1 for the participant to be eligible for the study. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •4.Has a life expectancy of at least 3 months.
- •5.Is male or female, who is at least 18 years of age at the time of signing the informed consent.
- •6.Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1, as assessed within 3 days of treatment initiation.
- •7.A male participant must agree to use contraception as detailed in Appendix 5 of this protocol during the treatment period and for at least 120 days (4 months), corresponding to time needed to eliminate any study intervention(s) and refrain from donating sperm during this period. Refer to Appendix 5 for additional guidance.
- •8.A female participant is eligible to participate if she is not pregnant (Appendix 5), not breastfeeding, and at least 1 of the following conditions applies:
- •Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.
- •A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during the treatment period and for at least 180 days (6 months) after the last dose of study intervention, corresponding to time needed to eliminate any study intervention(s).
- •9.The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for FBR. However, the participant may participate in the main study without participating in FBR.
- •10.Has adequate organ function, as detailed in Table 4 (see Protocol); all screening laboratory tests should be performed within 10 days prior to the first dose of study intervention.
排除标准
- •1.Has a known additional malignancy that is progressing or has required active treatment in the last 3 years.
- •2.Has a history of non-infectious pneumonitis that required treatment with steroids or currently has pneumonitis.
- •3.Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
- •4.Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •5.Has an active infection requiring systemic therapy.
- •6.Has active tuberculosis (Bacillus tuberculosis [TB]).
- •7.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- •8.Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- •9.Has a history or current evidence of any condition (eg, cytopenia, transfusion-dependent anemia, or thrombocytopenia), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant’s involvement for the full duration of the study, or is not in the best interest of the participant to be involved, in the opinion of the treating investigator.
- •10.Received colony-stimulating factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM CSF] or recombinant erythropoietin) within 28 days prior to the first dose of study intervention.
- •11.Is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan, uncontrollable bone pain, or any psychiatric disorder that prohibits obtaining informed consent.
- •12.Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
- •13.Has a known history of human immunodeficiency virus (HIV) infection. Testing for HIV at screening is only required if mandated by local health authority. Refer to Appendix 7 for country-specific requirements.
- •14.Has known active hepatitis (ie, Hepatitis B or C)
- •Active hepatitis B virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result. Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible.
- •Participants positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •15.Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, malabsorption).
- •16.A WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •17.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent di
研究者
相似试验
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerEUCTR2019-001745-40-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerEUCTR2019-001745-40-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.300
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerThe treatment of participants with HRRm and/or HRD-positive cancerMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-503831-17-00Merck Sharp & Dohme LLC425
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and/or HRD positivecancerHRRm and/or HRD-positive cancerMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2019-001745-40-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerEUCTR2019-001745-40-PLMerck Sharp & Dohme LLC300